International Biotechnology Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

International Biotechnology Trust’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$13.6M	Buy	153,656 +95,000	+162%	+$8.45M	4.58%	5
2023 Q2	$5.08M	Hold	58,656	–	–	1.55%	23
2023 Q1	$5.7M	Buy	58,656 +15,000	+34%	+$1.56M	1.59%	23
2022 Q4	$4.51M	Sell	43,656 -15,000	-26%	-$1.41M	1.39%	23
2022 Q3	$4.97M	Buy	58,656 +52,055	+789%	+$4.63M	1.59%	20
2022 Q2	$79.7K	Sell	6,601 -73,055	-92%	-$5.82M	0.83%	29
2022 Q1	$235K	Sell	79,656 -25,500	-24%	-$2.13M	0.05%	67
2021 Q4	$9.29M	Buy	105,156 +50,000	+91%	+$4.13M	2.07%	19
2021 Q3	$4.26M	Hold	55,156	–	–	1.03%	28
2021 Q2	$4.6M	Hold	55,156	–	–	1.22%	23
2021 Q1	$4.17M	Sell	55,156 -192,428	-78%	-$15.7M	1.1%	24
2020 Q4	$21.7M	Hold	247,584	–	–	5.92%	4
2020 Q3	$18.8M	Buy	247,584 +62,000	+33%	+$6.27M	6.07%	5
2020 Q2	$22.7M	Buy	185,584 +15,800	+9%	+$1.57M	7.54%	2
2020 Q1	$14.3M	Buy	169,784 +65,500	+63%	+$5.64M	6.54%	4
2019 Q4	$8.81M	Buy	104,284 +17,000	+19%	+$1.28M	3.18%	11
2019 Q3	$5.88M	Buy	87,284 +23,000	+36%	+$1.77M	2.72%	15
2019 Q2	$5.51M	Hold	64,284	–	–	2.04%	17
2019 Q1	$5.7M	Sell	64,284 -28,000	-30%	-$2.6M	2.11%	18
2018 Q4	$6.17M	Sell	92,284 -5,000	-5%	-$476K	3.83%	9
2018 Q3	$7.23M	Hold	97,284	–	–	3.44%	11
2018 Q2	$9.16M	Buy	97,284 +32,000	+49%	+$2.8M	3.52%	11
2018 Q1	$5.29M	Sell	65,284 -3,100	-5%	-$266K	2.06%	18
2017 Q4	$6.1M	Hold	68,384	–	–	2.15%	18
2017 Q3	$6.36M	Sell	68,384 -49,782	-42%	-$4.4M	2.48%	11
2017 Q2	$10.7M	Buy	118,166 +40,500	+52%	+$3.68M	4.08%	6
2017 Q1	$6.82M	Buy	77,666 +2,000	+3%	+$178K	2.61%	12
2016 Q4	$6.27M	Buy	+75,666	New	+$6.51M	2.82%	14

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

International Biotechnology Trust's BMRN Position: Q3 2023 in Review

International Biotechnology Trust increased its BioMarin Pharmaceuticals (BMRN) stake by 162% in Q3 2023, buying an estimated $8.45M and bringing the position to 153,656 shares worth $13.6M. The position accounts for 4.58% of the portfolio, ranked #5.

International Biotechnology Trust first reported a position in BMRN in Q4 2016 and has held it in 28 quarters since. The position peaked at $22.7M in Q2 2020. 520 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

International Biotechnology Trust held 153,656 shares of BioMarin Pharmaceuticals worth $13.6M as of Q3 2023.
International Biotechnology Trust bought 95,000 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $8.45M.
BioMarin Pharmaceuticals made up 4.58% of International Biotechnology Trust's portfolio in Q3 2023, its #5 holding.
International Biotechnology Trust first reported a position in BioMarin Pharmaceuticals in Q4 2016 and has held it in 28 quarters since.
International Biotechnology Trust's BioMarin Pharmaceuticals position peaked at $22.7M in Q2 2020.
520 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.